Search results for "genotype"

showing 10 items of 1725 documents

MRI findings and genotype analysis in patients with childhood onset growth hormone deficiency--correlation with severity of hypopituitarism.

2007

Aim: To evaluate the relationship between pituitary size, PIT1 and PROP1 genotype, and the severity of childhood onset growth hormone deficiency (coGHD). Patients: Forty-four patients with coGHD (34 M; 9.7 ± 4.1 years): severe isolated (SI) GHD (n = 14); partial isolated (PI) GHD (n = 13); multiple pituitary hormone deficiencies (MPHD) (n=17). Results: Pituitary abnormalities were found in 7/14 patients with SIGHD (50%), 16/17 patients with MPHD (94.1%), and no patient with PIGHD. Mean pituitary height (PHT SDS) was significantly lower in MPHD than in SIGHD and PIGHD. Pituitary height SDS and pituitary volume (PV) SDS correlated with IGF-I SDS and stimulated GH peaks in the SIGHD and MPHD g…

Malemedicine.medical_specialtyAdolescentGenotypeEndocrinology Diabetes and MetabolismGenotype AnalysisHypopituitarismHypopituitarismGrowth hormone deficiencyCorrelationEndocrinologyInternal medicineAge Determination by SkeletonGenotypemedicineHumansIn patientAge of OnsetChildDwarfism PituitaryRetrospective StudiesHomeodomain Proteinsbusiness.industrymedicine.diseaseMagnetic Resonance ImagingBody HeightEndocrinologyChild PreschoolPituitary GlandPediatrics Perinatology and Child HealthPituitary hormonesDisease ProgressionFemalebusinessTranscription Factor Pit-1Mri findingsJournal of pediatric endocrinologymetabolism : JPEM
researchProduct

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

2010

Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV) is the standard of care for adults with chronic hepatitis C but was not approved for the treatment of children at the time of this study. The aim of this study was to evaluate the efficacy and safety of PEG-IFN alfa-2b plus RBV in children.Children and adolescents ages 3-17 years were treated with PEG-IFN alfa-2b (60microg/m(2)/week) plus RBV (15mg/kg/day). The duration of therapy was 24 weeks for genotype (G) 2 and G3 patients with low viral load (600,000IU/ml) and 48 weeks for G1, G4, and G3 with high viral load (or=600,000IU/ml). The primary end point was sustained virologic response (SVR), defined as undetectable hepatitis C vi…

Malemedicine.medical_specialtyAdolescentGenotypeHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundChild DevelopmentPegylated interferonInternal medicineDrug Resistance ViralRibavirinmedicineHumansChildAdverse effectHepatologybusiness.industryRibavirinBody WeightInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseBody HeightRecombinant ProteinsTreatment OutcomechemistryChild PreschoolImmunologyPeginterferon alfa-2bDrug Therapy CombinationFemaleViral hepatitisbusinessViral loadmedicine.drugJournal of Hepatology
researchProduct

Role of environmental and genetic factor interaction in age-related disease development: the gastric cancer paradigm.

2008

The association of Helicobacter pylori (Hp) infection with gastric cancer is well known and might be considered a paradigmatic example of the role that interaction among environmental factors and individual background might play in inducing age-associated disease. To evaluate the role of interaction of Hp infection with genetic background, gastric cancer and chronic gastritis patients as well as random selected controls were typed for five inflammation-related polymorphisms of IL-1 and IL-10 cytokine genes. No association among IL-10 or IL-1 variants with an increased risk of gastric cancer was found, whereas an Hp-independent association of IL-1beta -511T positive genotypes to an increased…

Malemedicine.medical_specialtyAgingSettore MED/07 - Microbiologia E Microbiologia ClinicaGenotypemedicine.medical_treatmentChronic gastritisDiseaseEnvironmentGastroenterologyPolymorphism (computer science)Stomach NeoplasmsInternal medicineGenotypemedicineHumansSettore MED/05 - Patologia ClinicaDiseaseGrading (tumors)Polymorphism GeneticbiologyCancercytokine genes biomarkersHelicobacter pylorimedicine.diseasebiology.organism_classificationCytokineGastritisImmunologyCytokinesFemaleGeriatrics and GerontologyH. pylori
researchProduct

Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension.

1999

We investigated the influence of major cardiovascular risk factors (smoking, hypercholesterolemia, diabetes mellitus) on the association between angiotensin-converting enzyme (ACE) gene insertion (I)/deletion (D) polymorphism and echocardiographic left ventricular mass in 225 patients with sustained hypertension, assessed by ambulatory blood pressure monitoring. When the study population was analyzed as a whole, the 3 ACE genotypes did not differ in left ventricular mass (II, 47 g/m2.7; ID, 49 g/m2.7; DD, 51 g/m2.7; p = NS). No difference was found in subjects (n = 135) in whom at least 1 major cardiovascular risk factor was present (II, 51 g/m2.7; ID, 51 g/m2.7; DD: 52 g/m2.7; p = NS). In …

Malemedicine.medical_specialtyAmbulatory blood pressureGenotypeHeart VentriclesPeptidyl-Dipeptidase ALeft ventricular hypertrophyPolymerase Chain ReactionMuscle hypertrophyRisk FactorsInternal medicineDiabetes mellitusmedicineHumansRisk factorAllelesRetrospective StudiesPolymorphism Geneticbiologybusiness.industryAngiotensin-converting enzymeOdds ratioDNABlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseasePrognosisEchocardiography DopplerCardiovascular DiseasesHypertensionCardiologybiology.proteinPopulation studyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessGene DeletionFollow-Up Studies
researchProduct

Cholesterol and saturated fat intake determine the effect of polymorphisms at ABCG5/ABCG8 genes on lipid levels in children.

2006

Purpose: Analysis of mutations in genes of the cholesterol metabolic pathway has not completely explained the interindividual variability of blood cholesterol concentrations attributed to gene–nutrient interactions. Thus, we analyzed polymorphisms in the ABCG5 and ABCG8 genes, involved in the regulation of intestinal cholesterol absorption, with special interest in a potential interaction with diet to determine lipid levels. Methods: The polymorphisms ABCG5 C1950G (Gln604Glu) and ABCG8 C1895T (Ala640Val) were determined by polymerase chain reaction and restriction analysis in 1227 healthy school children, aged 6 to 8 years. Results: No significant differences were found in blood lipid level…

Malemedicine.medical_specialtyApolipoprotein BLipoproteinsBlood lipidsABCG8Cholesterol Dietarychemistry.chemical_compoundGene FrequencyPolymorphism (computer science)Internal medicineSurveys and QuestionnairesGenotypemedicineHumansATP Binding Cassette Transporter Subfamily G Member 5ChildGenetics (clinical)GeneticsPolymorphism GeneticbiologyBase SequenceCholesterolATP Binding Cassette Transporter Subfamily G Member 8DNADietary FatsLipidsEndocrinologychemistryABCG5biology.proteinIntestinal cholesterol absorptionlipids (amino acids peptides and proteins)ATP-Binding Cassette TransportersFemaleGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Genetic and environmental influences on the fibrinolytic system: a twin study.

2004

SummaryThe determination of heritability is a key issue to assess the predictive power of polymorphisms for disease in clinical studies. The aim of this study was to determine the heritability of proteins and activation markers of the fibrinolytic system in a large cohort of healthy twins. Heritability was calculated as 0.76 for thrombin activatable fibrinolysis inhibitor (TAFI), 0.44 for plasminogen activator inhibitor-1 (PAI-1), and 0.43 for tissue plasminogen activator. No significant genetic influence was observed for α2-antiplasmin-plasmin-complex and D-dimer. Heritability explained by single gene polymorphisms was 25.2% for TAFI 505G>A, 31.5% for 1542C>G, and 50.0% for combinati…

Malemedicine.medical_specialtyCarboxypeptidase B2GenotypeArteriosclerosismedicine.medical_treatmentBiologyEnvironmentTissue plasminogen activatorCohort StudiesFibrin Fibrinogen Degradation ProductsInternal medicineFibrinolysisPlasminogen Activator Inhibitor 1medicineDiseases in TwinsHumansFibrinolysinGeneGeneticsalpha-2-AntiplasminPolymorphism GeneticActivator (genetics)FibrinolysisHematologyTwins MonozygoticHeritabilityTwin studyEndocrinologyPhenotypeHaplotypesHemostasisTwin Studies as TopicFemalePlasminogen activatormedicine.drugThrombosis and haemostasis
researchProduct

Dietary fat interacts with the -514CT polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: th…

2003

We have previously reported an interaction between -514CT polymorphism at the hepatic lipase (HL) gene and dietary fat on high-density lipoprotein-cholesterol (HDL-C) metabolism in a representative sample of white subjects participating in the Framingham Heart Study. Replication of these findings in other populations will provide proof for the relevance and consistency of this marker as a tool for risk assessment and more personalized cardiovascular disease prevention. Therefore, we examined this gene-nutrient interaction in a representative sample of Singaporeans (1324 Chinese, 471 Malays and 375 Asian Indians) whose dietary fat intake was recorded by a validated questionnaire. When no str…

Malemedicine.medical_specialtyChinaGenotypeMedicine (miscellaneous)IndiaBiologyPolymerase Chain ReactionPolymorphism Single Nucleotidechemistry.chemical_compoundFramingham Heart StudyAsian PeopleInternal medicineGenotypeBlood plasmamedicineEthnicityHumansPromoter Regions GeneticTriglyceridesDNA PrimersNutrition and Dieteticsmedicine.diagnostic_testTriglycerideBase SequenceCholesterolConfoundingMalaysiaLipaseDietary FatsEndocrinologychemistryLiverFemaleHepatic lipaseLipid profileThe Journal of nutrition
researchProduct

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?

2007

The on-treatment virological response to pegylated interferon plus ribavirin therapy is a useful tool in the management of patients with chronic hepatitis C. The time at which hepatitis C virus RNA becomes undetectable by a sensitive PCR assay has a huge impact on the probability of achieving a sustained virological response, particularly in genotype 1 patients, and may be useful in selecting patients for prolonged therapy. Indiscriminate extension of treatment in patients with hepatitis C virus genotype 1 is not beneficial. However, there is a subgroup of patients – the so-called ‘slow responders’ – who benefit from extending treatment from 48 to 72 weeks and can be readily identified afte…

Malemedicine.medical_specialtyCombination therapyGenotypeHepatitis C virusHepacivirusProlonged therapyHepacivirusInterferon alpha-2Chronic hepatitis Cmedicine.disease_causeGastroenterologyAntiviral AgentsDrug Administration SchedulePolyethylene Glycolschemistry.chemical_compoundInterferonPegylated interferonInternal medicineRibavirinmedicineHumansCombination therapyPeginterferonRapid virological responseViral kineticsExtended treatmentHepatologybiologybusiness.industryRibavirinPatient SelectionInterferon-alphaHepatitis C Chronicbiology.organism_classificationRecombinant ProteinsRegimenchemistryImmunologyRNA ViralDrug Therapy CombinationFemalebusinessPegylated interferonPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct

Mutations in the HFE gene and cardiovascular disease risk: an individual patient data meta-analysis of 53 880 subjects.

2008

Background— Whether mutations in the hemochromatosis (HFE) gene increase cardiovascular disease risk is still undetermined. The main reason is the low frequency of the mutations, in particular of the compound C282Y/H63D genotype. We combined the data of 11 observational studies for an individual patient data meta-analysis. Methods and Results— Individual patient data were obtained from published as well as unpublished studies that had information available on the C282Y mutation as well as the H63D mutation in relation to coronary heart disease risk. Individual records were provided on each of the 53 880 participants in 11 studies. In total, 10 541 patients with coronary events were documen…

Malemedicine.medical_specialtyCompound heterozygositymeta-analysicardiovascular diseases; epidemiology; meta-analysis; myocardial infarction; risk factorscardiovascular diseaseRisk FactorsInternal medicineEpidemiologyGenotypeGeneticsOdds RatioMedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionHemochromatosis ProteinGenetics (clinical)HemochromatosisSettore MED/04 - Patologia GeneraleFramingham Risk Scorebusiness.industryHistocompatibility Antigens Class IMembrane ProteinsOdds ratioMiddle Agedmedicine.diseasemyocardial infarctionCardiovascular DiseasesMeta-analysisMutationCardiologyepidemiologyFemaleCardiology and Cardiovascular MedicinebusinessCirculation. Cardiovascular genetics
researchProduct

Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozy…

2001

Aims To assess the relationship of the lipid profile to coronary heart disease in a group of heterozygous familial hypercholesterolaemic subjects with similar age, sex, body mass index, prevalence of angiotensin converting enzyme DD genotype and type of low density lipoprotein receptor mutation. Methods and Results A total of 66 molecularly defined heterozygous familial hypercholesterolaemic subjects, 33 of whom had coronary heart disease, were studied. Clinical features, cardiovascular risk factors and lipid parameters were compared in both groups. Familial hypercholesterolaemic patients with coronary heart disease showed significantly lower values of mean plasma HDL cholesterol and a high…

Malemedicine.medical_specialtyGenotypeCoronary DiseasePeptidyl-Dipeptidase AHyperlipoproteinemia Type IIchemistry.chemical_compoundRisk FactorsStatistical significanceInternal medicinemedicineHumansRisk factorReceptors Lipoproteinbiologymedicine.diagnostic_testCholesterolbusiness.industryCholesterol HDLCase-control studyAngiotensin-converting enzymeMiddle AgedEndocrinologyBlood pressurechemistrySpainCase-Control StudiesMutationCardiologybiology.proteinRegression AnalysisFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessLipid profileBody mass indexEuropean Heart Journal
researchProduct